AstraZeneca said on Monday (June 27) two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the company's oncology portfolio.
Lynparza, a cancer drug developed jointly with U.S.-based Merck, was backed for standalone use or in combination with endocrine therapy in adults with a form of genetically mutated early-stage breast cancer.
The drug, which has received a similar recommendation in the United States in March, is a key asset for AstraZeneca. It was recommended in patients with low-to-normal levels of a protein known as HER2 that is the target of several new therapies.
Enhertu -- developed jointly with Japan's Daiichi Sankyo (4568.T) -- was the other drug that was endorsed by the European Medicines Agency for treating an aggressive form of breast cancer characterised by a high rate of HER2.
Enhertu is seen as a major growth driver for AstraZeneca, with some analysts expecting peaks sales of $10 billion. The drug is also expected to be cleared for patients with low levels of HER2 this month after the recent success of a trial.
Cat Smith, Labour MP for Lancaster and Wyre